Daito Pharmaceutical Co.,Ltd. [4577.T]
TOKYO, Apr 10 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) reported consolidated results for Q3 FY2026 (ending May 2026).
Revenue was ¥36.7 billion (+0.3% YoY). operating profit was ¥2,751 million (+47.2%). net profit attributable to shareholders was ¥2,267 million (+86.2%).
Total assets stood at ¥75.0 billion with an equity ratio of 69.7%. The company declared an annual dividend of ¥20 per share. The full-year forecast for the current fiscal year is revenue of ¥51.0 billion (+0.7%).
Financial results — FY2026/5 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥36,732M | +0.3% |
| Operating profit | ¥2,751M | +47.2% |
| Net profit | ¥2,267M | +86.2% |
Next period forecast
Revenue
¥51,000M
+0.7%Op. profit
¥3,300M
+26.0%Net profit
¥2,500M
+31.0%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.